Molecular profiling and safety study of operable lung cancer patients treated with Alimta [pemetrexed] combined with cisplatin as neoadjuvant chemotherapy.

Trial Profile

Molecular profiling and safety study of operable lung cancer patients treated with Alimta [pemetrexed] combined with cisplatin as neoadjuvant chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2011

At a glance

  • Drugs Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jan 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top